News|Videos|June 19, 2024
Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM
Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman details the new IMS/IMWG consensus definition of cure for multiple myeloma, requiring 5 years of treatment-free remission.
Beth Faiman, PhD, and Sikander Ailawadhi, MD, discuss clinic workflows, safety checks, and at-home dosing potential for on-body isatuximab.
Discover how equine-assisted services support patients with cancer by improving emotional wellness, building confidence, and enhancing quality of life.
Two Winship nurses explain how to talk with breast cancer survivors about GLP-1 receptor agonists, from endocrine therapy to access barriers.
ABUS matched handheld ultrasound on cancer detection in women with dense breasts while lowering recall and short-interval follow-up rates.
A Moffitt nurse practitioner explains rollout, handling, triage, and patient education for nogapendekin alfa inbakicept-pmln plus BCG.
Life table analysis estimates residual ovarian cancer risk by current age and planned age at risk-reducing surgery.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
Automated Breast Ultrasound Tied to Fewer False-Positives in Dense Breasts
2
Beyond the Treatment Center: Exploring Equine Assisted Wellness
3
Delaying BSO to Age 50 Leaves BRCA1 Carriers With 24% Ovarian Cancer Risk
4
Future Directions in Metastatic Triple-Negative Breast Cancer Care
5